Allogeneic somatic cell therapy: Process development challenges and future opportunities

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 4, 2010, Pages 383-385

  Fawaz, F S ^a   Hermiston, Terry W ^a   Dinter, H ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION; CELL EXPANSION; CELL ISOLATION; CELL SCREENING; CRYOPRESERVATION; DONOR; HUMAN; ORGAN TRANSPLANTATION; PARKINSON DISEASE; PRODUCT DEVELOPMENT; RESEARCH; REVIEW; SCALE UP; SHELF LIFE; SHIPPING; SOMATIC CELL THERAPY; TISSUE CHARACTERIZATION; TISSUE PRESERVATION; ANIMAL; BIOLOGICAL THERAPY; CELL PROLIFERATION; PROCEDURES; TIME; TRANSPLANTATION; TRENDS;

ANIMALS; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; HUMANS; TIME FACTORS; TISSUE AND ORGAN HARVESTING;

EID: 77955363839     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (2)

1. Meyer AK, Maisel M, Hermann A, Stirl K, Storch A: Restorative approaches in Parkinsons disease: Which cell type wins the race? J Neurol Sci (2010) 289(1-2):93-103.
2. Cellular, Tissue and Gene Therapies Advisory Committee Meeting 41: Potency measurements for cellular and gene therapy products. FDA, Silver Spring, MD, USA (2006). www.fda.gov/ohrms/dockets/ac/06/slides/2006-4205s1.htm